The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells

Stem Cells and Development

Volumn 23, Issue 9, 2014, Pages 955-967

  Thordardottir, Soley ^a   Hangalapura, Basav N ^a   Hutten, Tim ^a   Cossu, Marta ^b   Spanholtz, Jan ^c   Schaap, Nicolaas ^a   Radstake, Timothy R D J ^b   Van Der Voort, Robbert ^a   Dolstra, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Glycostem Therapeutics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; AROMATIC HYDROCARBON RECEPTOR; CD34 ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 12; PEPTIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; DIFFERENTIATION ANTIGEN; PURINE DERIVATIVE; STEMREGENIN 1;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYELOID DENDRITIC CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION; VACCINATION; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CLINICAL TRIAL; CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; FEMALE; FETUS BLOOD; MALE; METABOLISM; PLASMA CELL;

ANTIGENS, DIFFERENTIATION; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MYELOID CELLS; PLASMA CELLS; PURINES; RECEPTORS, ARYL HYDROCARBON;

EID: 84899100948     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0521     Document Type: Article

References (55)

1. Steinman RM and J Banchereau. (2007). Taking dendritic cells into medicine. Nature 449:419-426.
2. Palucka K, J Banchereau and I Mellman. (2010). Designing vaccines based on biology of human dendritic cell subsets. Immunity 33:464-478.
3. Hilkens CM and JD Isaacs. (2013). Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol 172:148-157.
4. Figdor CG, IJ de Vries, WJ Lesterhuis and CJ Melief. (2004). Dendritic cell immunotherapy: mapping the way. Nat Med 10:475-480.
5. Palucka K and J Banchereau. (2012). Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-277.
6. Draube A, N Klein-Gonzalez, S Mattheus, C Brillant, M Hellmich, A Engert and M von Bergwelt-Baildon. (2011). Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6:e18801.
7. Tel J, EH Aarntzen, T Baba, G Schreibelt, BM Schulte, D Benitez-Ribas, OC Boerman, S Croockewit, WJ Oyen, et al. (2013). Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73:1063-1075.
8. Nierkens S, MH den Brok, Z Garcia, S Togher, J Wagenaars, M Wassink, L Boon, TJ Ruers, CG Figdor, et al. (2011). Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 71:6428-6437.
9. Iwasaki A and R Medzhitov. (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995.
10. Piccioli D, S Tavarini, E Borgogni, V Steri, S Nuti, C Sammicheli, M Bardelli, D Montagna, F Locatelli and A Wack. (2007). Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 109:5371-5379.
11. Liu YJ. (2005). IPC: professional type 1 interferonproducing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306.
12. Yoneyama H, K Matsuno, E Toda, T Nishiwaki, N Matsuo, A Nakano, S Narumi, B Lu, C Gerard, S Ishikawa and K Matsushima. (2005). Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 202:425-435.
13. Piccioli D, C Sammicheli, S Tavarini, S Nuti, E Frigimelica, AG Manetti, A Nuccitelli, S Aprea, S Valentini, et al. (2009). Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 113:4232-4239.
14. Jounai K, K Ikado, T Sugimura, Y Ano, J Braun and D Fujiwara. (2012). Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. PLoS One 7:e32588.
15. Lou Y, C Liu, GJ Kim, YJ Liu, P Hwu and G Wang. (2007). Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178:1534-1541.
16. Kuwajima S, T Sato, K Ishida, H Tada, H Tezuka and T Ohteki. (2006). Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 7:740-746.
17. Casado FL, KP Singh and TA Gasiewicz. (2010). The aryl hydrocarbon receptor: regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol Dis 44:199-206.
18. Boitano AE, J Wang, R Romeo, LC Bouchez, AE Parker, SE Sutton, JR Walker, CA Flaveny, GH Perdew, et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:1345-1348.
19. Platzer B, S Richter, D Kneidinger, D Waltenberger, M Woisetschlager and H Strobl. (2009). Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol 183:66-74.
20. Overes IM, B de Rijke, A van Horssen-Zoetbrood, H Fredrix, AO de Graaf, JH Jansen, JH van Krieken, RA Raymakers, R van der Voort, TM de Witte and H Dolstra. (2008). Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol 141:799-807.
21. de Rijke B, A van Horssen-Zoetbrood, JM Beekman, B Otterud, F Maas, R Woestenenk, M Kester, M Leppert, AV Schattenberg, et al. (2005). A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 115:3506-3516.
22. Hobo W, K Broen, WJ van der Velden, A Greupink-Draaisma, N Adisty, Y Wouters, M Kester, H Fredrix, JH Jansen, et al. (2013). Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19:274-282.
23. Chen W, S Antonenko, JM Sederstrom, X Liang, AS Chan, H Kanzler, B Blom, BR Blazar and YJ Liu. (2004). Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood 103:2547-2553.
24. Blom B, S Ho, S Antonenko and YJ Liu. (2000). Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 192:1785-1796.
25. Murray LJ, JC Young, LJ Osborne, KM Luens, R Scollay and BL Hill. (1999). Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34 + cells and recruit primitive CD34 + Thy-1 + cells into rapid division. Exp Hematol 27:1019-1028.
26. Dzionek A, A Fuchs, P Schmidt, S Cremer, M Zysk, S Miltenyi, DW Buck and J Schmitz. (2000). BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165:6037-6046.
27. Hemont C, A Neel, M Heslan, C Braudeau and R Josien. (2013). Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J Leukoc Biol 93:599-609.
28. Guiducci C, G Ott, JH Chan, E Damon, C Calacsan, T Matray, KD Lee, RL Coffman and FJ Barrat. (2006). Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203:1999-2008.
29. Kerkmann M, S Rothenfusser, V Hornung, A Towarowski, M Wagner, A Sarris, T Giese, S Endres and G Hartmann. (2003). Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 170:4465-4474.
30. Tel J, G Schreibelt, SP Sittig, TS Mathan, SI Buschow, LJ Cruz, AJ Lambeck, CG Figdor and IJ de Vries. (2013). Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8 + T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121:459-467.
31. Hoeffel G, AC Ripoche, D Matheoud, M Nascimbeni, N Escriou, P Lebon, F Heshmati, JG Guillet, M Gannage, et al. (2007). Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 27:481-492.
32. Joffre OP, E Segura, A Savina and S Amigorena. (2012). Cross-presentation by dendritic cells. Nat Rev Immunol 12:557-569.
33. Liu C, Y Lou, G Lizee, H Qin, S Liu, B Rabinovich, GJ Kim, YH Wang, Y Ye, et al. (2008). Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118:1165-1175.
34. Diamond MS, M Kinder, H Matsushita, M Mashayekhi, GP Dunn, JM Archambault, H Lee, CD Arthur, JM White, et al. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:1989-2003.
35. Salio M, MJ Palmowski, A Atzberger, IF Hermans and V Cerundolo. (2004). CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med 199:567-579.
36. Schreibelt G, LJ Klinkenberg, LJ Cruz, PJ Tacken, J Tel, M Kreutz, GJ Adema, GD Brown, CG Figdor and IJ de Vries. (2012). The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3 + myeloid dendritic cells. Blood 119:2284-2292.
37. Poulin LF, M Salio, E Griessinger, F Anjos-Afonso, L Craciun, JL Chen, AM Keller, O Joffre, S Zelenay, et al. (2010). Characterization of human DNGR-1 + BDCA3 + leukocytes as putative equivalents of mouse CD8alpha + dendritic cells. J Exp Med 207:1261-1271.
38. Nizzoli G, J Krietsch, A Weick, S Steinfelder, F Facciotti, P Gruarin, A Bianco, B Steckel, M Moro, et al. (2013). Human CD1c + dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 122:932-942.
39. Schotte R, H Schmidlin, M Nagasawa, W Dontje, JJ Karrich, C Uittenbogaart, H Spits and B Blom. (2010). Isolation and in vitro generation of gene-manipulated human plasmacytoid and conventional dendritic cells. Methods Mol Biol 595:67-85.
40. Proietto AI, D Mittag, AW Roberts, N Sprigg and L Wu. (2012). The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro fromhuman CD34(+) stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. Cell Mol Immunol 9:446-454.
41. Demoulin S, P Roncarati, P Delvenne and P Hubert. (2012). Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: use of interleukin-3. Exp Hematol 40:268-278.
42. Spanholtz J, F Preijers, M Tordoir, C Trilsbeek, J Paardekooper, T de Witte, N Schaap and H Dolstra. (2011). Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6:e20740.
43. Hobo W, TI Novobrantseva, H Fredrix, J Wong, S Milstein, H Epstein-Barash, J Liu, N Schaap, R van der Voort and H Dolstra. (2013). Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 62:285-297.
44. Stevens EA, JD Mezrich and CA Bradfield. (2009). The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127:299-311.
45. Esser C, A Rannug and B Stockinger. (2009). The aryl hydrocarbon receptor in immunity. Trends Immunol 30: 447-454.
46. Nguyen NT, H Hanieh, T Nakahama and T Kishimoto. (2013). The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 25:335-343.
47. Singh KP, RW Garrett, FL Casado and TA Gasiewicz. (2011). Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions. Stem Cells Dev 20:769-784.
48. Schmidt JV, GH Su, JK Reddy, MC Simon and CA Bradfield. (1996). Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A 93:6731-6736.
49. Thurmond TS, JE Staples, AE Silverstone and TA Gasiewicz. (2000). The aryl hydrocarbon receptor has a role in the in vivo maturation of murine bone marrow B lymphocytes and their response to 2,3,7,8-tetrachlorodibenzo-pdioxin. Toxicol Appl Pharmacol 165:227-236.
50. Hirabayashi Y and T Inoue. (2009). Aryl hydrocarbon receptor biology and xenobiotic responses in hematopoietic progenitor cells. Biochem Pharmacol 77:521-535.
51. Liu H, I Ramachandran and DI Gabrilovich. (2013). Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunol Cell Biol DOI: 10.1038/icb.2013.65.
52. Vorderstrasse BA and NI Kerkvliet. (2001). 2,3,7,8-Tetrachlorodibenzo-p- dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol Appl Pharmacol 171:117-125.
53. Albanesi C, C Scarponi, D Bosisio, S Sozzani and G Girolomoni. (2010). Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity 43:215-219.
54. Kirou KA and E Gkrouzman. (2013). Anti-interferon alpha treatment in SLE. Clin Immunol 148:303-312.
55. Radstake TR, AW van Lieshout, PL van Riel, WB van den Berg and GJ Adema. (2005). Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis 64:1532-1538.